Technical Analysis for RGT - Argent Biopharma Limited
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | -5.33% | |
| Hot IPO Pullback | Bullish Swing Setup | -5.33% | |
| Hot IPO Pullback | Bullish Swing Setup | -6.58% | |
| NR7 | Range Contraction | -6.58% | |
| Narrow Range Bar | Range Contraction | -6.58% | |
| Inside Day | Range Contraction | -6.58% | |
| Hot IPO Pullback | Bullish Swing Setup | -6.58% | |
| Doji - Bullish? | Reversal | -6.58% | |
| Gapped Down | Weakness | -12.35% | |
| Hot IPO Pullback | Bullish Swing Setup | -6.58% |
| Alert | Time |
|---|---|
| Fell Below Previous Day's Low | 30 minutes ago |
| 2x Volume Pace | 30 minutes ago |
| Down 5% | 30 minutes ago |
| Down 3% | 30 minutes ago |
| Down 2% | 30 minutes ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
Argent BioPharma Limited, a drug discovery clinical-stage biopharmaceutical company, provides medicines targeting immunology and neurology worldwide. Its principal product candidates include CimetrA, which is in phase II clinical trial for the treatment of SLE Lupus, anti-inflammatory, and SARS COVID-19; and CannEpil, which is in phase I clinical trial for refractory epilepsy and cerebral palsy; and CogniCann, which is in phase I clinical trial for the symptomatic relief of Dementia and Alzheimer. In addition, the company provides Irnican for brain cancer. The company was formerly known as MGC Pharmaceuticals Limited and changed it name to Argent BioPharma Limited. Argent BioPharma Limited was founded in 2014 and is based in Subiaco, Australia.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Biopharmaceutical Drug Discovery Dementia Brain Cancer Cerebral Palsy
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Biopharmaceutical Drug Discovery Dementia Brain Cancer Cerebral Palsy
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 0.41 |
| 52 Week Low | 0.37 |
| Average Volume | 3,174 |
| 200-Day Moving Average | 0.000 |
| 50-Day Moving Average | 0.000 |
| 20-Day Moving Average | 0.000 |
| 10-Day Moving Average | 0.384 |
| Average True Range | 0.000 |
| RSI (14) | 0.00 |
| ADX | 0.0 |
| +DI | 0.000 |
| -DI | 0.000 |
| Chandelier Exit (Long, 3 ATRs) | N/A |
| Chandelier Exit (Short, 3 ATRs) | N/A |
| Upper Bollinger Bands | 0.000 |
| Lower Bollinger Band | 0.000 |
| Percent B (%b) | 0.0 |
| BandWidth | 0.000 |
| MACD Line | -0.002 |
| MACD Signal Line | 0.000 |
| MACD Histogram | -0.0013 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.383 | ||||
| Resistance 3 (R3) | 0.383 | 0.382 | 0.381 | ||
| Resistance 2 (R2) | 0.382 | 0.380 | 0.381 | 0.381 | |
| Resistance 1 (R1) | 0.378 | 0.379 | 0.378 | 0.378 | 0.380 |
| Pivot Point | 0.377 | 0.377 | 0.376 | 0.376 | 0.377 |
| Support 1 (S1) | 0.373 | 0.375 | 0.373 | 0.373 | 0.370 |
| Support 2 (S2) | 0.372 | 0.374 | 0.371 | 0.369 | |
| Support 3 (S3) | 0.368 | 0.372 | 0.369 | ||
| Support 4 (S4) | 0.368 |
